-
Supplement product lines and extend sales market... Since August, multiple pharmaceutical companies have launched mergers and acquisitions
Time of Update: 2022-08-20
According to the announcement, Sino-US Huadong will invest a total of no more than 396 million yuan to obtain a 60% stake in Huaren Technology and become its controlling shareholder by means of capital increase and transfer of shares .
-
This pharmaceutical company accounted for one-fifth of the 16 large-scale mergers and acquisitions in the first half of the year
Time of Update: 2022-08-15
[Pharmaceutical Network Enterprise News] In order to cope with problems such as the imminent expiration of original research drugs, patent cliffs, intensified competition in the industry, and declining profits of generic drugs, many large pharmaceutical companies in recent years have begun to strengthen their research and development pipelines through continuous mergers and acquisitions.
-
On February 18, these pharmaceutical companies issued announcements related to personnel changes, mergers and acquisitions, etc.
Time of Update: 2022-03-02
Microchip Bio: The application for the issuance of convertible bonds to unspecified objects passed the microchip bio announcement that the Shanghai Stock Exchange Science and Technology Innovation Board Listing Committee held the ninth listing committee review meeting in 2022 on February 17, 2022.
-
This week, a group of pharmaceutical companies spent huge sums of money to launch large-scale mergers and acquisitions!
Time of Update: 2022-02-21
Cosette is a manufacturer of dermatological products with high-quality production facilities for the manufacture of various pharmaceutical dosage forms such as suppositories, creams, ointments, liquids and gels, and is active in the field of dermatology and the treatment of allergic diseases R&D pipeline .
-
18 large international pharmaceutical companies with 1.72 trillion US dollars, will mergers and acquisitions explode in 2022?
Time of Update: 2022-02-21
S. pharma and life sciences consulting solutions leader, said 2022 could be a "pretty active year" for biopharma M&A, not just because Big Pharma amassed a lot of cash, but also because pharma companies The need to scale and diversify across different therapeutic areas remains evident .
-
In 2022, the wave of mergers and acquisitions of pharmaceutical companies is coming?
Time of Update: 2021-12-30
The purpose of continuous mergers and acquisitions by large pharmaceutical companies includes enhancing R&D pipelines, investing in blockbuster drugs under research or about to be launched, complementation of product portfolios and synergistic effects of scale, and so on .
-
At the end of the year, the wave of mergers and acquisitions of pharmaceutical companies continued!
Time of Update: 2021-12-26
In recent years, due to the difficulty, time-consuming, labor-intensive, and costly research and development of new drugs, many pharmaceutical companies have vigorously made some new investment arrangements in order to increase corporate operating profits, enrich drug pipelines, and reduce R&D expenditures .
-
Global pharmaceutical companies hundreds of billions of dollars in mergers and acquisitions! Ayr built the most of the Shire's most trenches
Time of Update: 2021-02-21
This year alone, drug companies have made hundreds of millions of mergers and acquisitions, amounting to $94.7 billion.
The acquisition of Tobira allowed Eljian to acquire two of the company's candidates for non-alcoholic fatty liver disease, Cenicriviroc and Evogliptin, as well as drugs for liver disease.
-
Pharmaceutical companies to start mergers and acquisitions boom intellectual property protection as the focus
Time of Update: 2021-02-20
Zhao Xu, an associate professor at the School of Intellectual Property at East China University of Political Science and Law, points out that one of the risks of mergers and acquisitions is intellectu
-
The pharmaceutical industry is now a large-scale mergers and acquisitions of multinational pharmaceutical companies, the third in 1 month!
Time of Update: 2020-11-17
September 13, local time, Gilead announced that it would buy biotech company Immunomedics for about $21 billion to acquire Trodelvy, the latter's original drug, to expand its cancer treatment business.
-
In the second half of 2020, the volume of mergers and acquisitions of pharmaceutical companies rebounded
Time of Update: 2020-11-13
Pharmaceutical Network Industry Dynamics: Mergers and acquisitions are often a big driver of big pharmaceutical companies' earnings, but in the first half of 2020, the number and volume of deals in the pharmaceutical and life sciences industries around the world fell, and fell to at least four-year lows, compared with 10 large trading years of more than $1 billion at the end of 2019.
-
In the coming months, a group of multinational pharmaceutical companies may engage in mergers and acquisitions
Time of Update: 2020-11-11
In 2019, the biotechnology sector executed more than 25 acquisitions, 14 of which exceeded $1 billion, according to Pharma.com Market Analysis. analysis points out that although the industry in 2020
-
What is the impact on pharmaceutical companies when the tide of mergers and acquisitions continues?
Time of Update: 2020-11-07
fact, in the pharmaceutical industry concentration increased, do not want to be eliminated pharmaceutical companies will certainly accelerate production, research and development and other transformation and upgrading.
-
The future of pharmaceutical companies - mergers and acquisitions.
Time of Update: 2020-08-22
2, the driving force of mergers and acquisitions of the pharmaceutical industry is the market economy environment to achieve the integration of resources in the industry, enterprises to obtain sustained revenue growth, accelerate the efficiency of new drug research and development of an important way, large pharmaceutical companies are carrying out a large number of mergers and acquisitions transactions, according to incomplete statistics, since 2010 the total number of global TOP10 pharmaceutical companies has reached nearly 500 billion U.S. dollars.
-
The general trend of mergers and acquisitions in the pharmaceutical industry is obvious, and pharmaceutical companies are speeding up their running.
Time of Update: 2020-07-30
Pharmaceutical Network Industry Dynamics: On July 27, Dongcheng Pharmaceuticals announced that its wholly-owned subsidiary Andico will acquire a 48.3084% stake in Meddo Bio (corresponding to a registered capital of 949.37 million yuan) for 96.65 million yuan in cash.